Correspondence to editorial on “Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab/ bevacizumab failure: A real-world study”

키워드

참고문헌 (19)

1. Nishida N, "Atezolizumab and bevacizumab for hepatocellular carcinoma : How to approach salvage therapy for non-responders? : Editorial on"Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab", bevacizumab failure : A real-world study", 2024, pp.30, 682~688
2. Cheon J, "Efficacy of nivolumab and ipilimumab in patients with hepatocellular carcinoma with prior immune-checkpoint inhibitor treatment", J Clin Oncol, 41(4 Suppl), pp.554~ (2023)
3. Wong JSL, "Ipilimumab and nivolumab", pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors, 2021, pp.9, e001945~
4. Roessler D, "Ipilimumab and nivolumab in advanced hepatocellular carcinoma after failure of prior immune checkpoint inhibitor-based combination therapies : a multicenter retrospective study", J Cancer Res Clin Oncol, 149, pp.3065~3073 (2023)
5. Buchbinder EI, "CTLA-4 and PD-1 pathways : similarities, differences, and implications of their inhibition", Am J Clin Oncol, 39, pp.98~106 (2016)
6. Li Z, "Regorafenib combined with PD-1 monoclonal antibody in the second-line setting for hepatocellular carcinoma(HCC) : A retrospective, real-world study in China", J Clin Oncol, 40(16Suppl), pp.e16145~ (2022)
7. Ma L, "959P Combination therapy of envafolimab and suvemcitug in patients with hepatocellular carcinoma(HCC) : Results from a phase II clinical trial", Ann Oncol, 34(Suppl 2), pp.S599~S600 (2023)
8. Kudo M, "Updated efficacy and safety of KEYNOTE-224 : a phase II study of pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib", Eur J Cancer, 167, pp.1~12 (2022)
9. Finn RS, "Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma", J Clin Oncol, 38, pp.2960~2970 (2020)
10. Kelley RK, "Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma(COSMIC-312) : a multicentre, open-label, randomised, phase 3 trial", Lancet Oncol, 23, pp.995~1008 (2022)
11. Ren Z, "Sintilimab plus a bevacizumab biosimilar(IBI305)versus sorafenib in unresectable hepatocellular carcinoma(ORIENT-32) : a randomised, open-label, phase 2-3 study", Lancet Oncol, 22, pp.977~990 (2021)
12. Liu Y, "Dissecting the role of the FGF19-FGFR4 signaling pathway in cancer development and progression", Front Cell Dev Biol, 8, pp.95~ (2020)
13. Lee YH, "Combinational immunotherapy for hepatocellular carcinoma : Radiotherapy, immune checkpoint blockade and beyond", Front Immunol, 11, pp.568759~ (2020)
14. Park B, "The effect of radiation on the immune response to cancers", Int J Mol Sci, 15, pp.927~943 (2014)
15. Sindhu KK, "Oligoprogression of solid tumors on immune checkpoint inhibitors : The impact of local ablative radiation therapy", Biomedicines, 10, pp.2481~ (2022)
16. Zhu M, "Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus : A multicenter, single-arm, phase 2 study", Hepatology, 80, pp.807~815 (2024)
17. Singal AG, "Real-world effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice", Cancer Rep(Hoboken), 6, pp.e1679~ (2023)
18. Muto H, "Clinical outcomes with lenvatinib in patients previously treated with atezolizumab", bevacizumab for advanced hepatocellular carcinoma, 2023, pp.43, 4673~4682
19. Chon YE, "Sorafenib vs. Lenvatinib in advanced hepatocellular carcinoma after atezolizumab", bevacizumab failure : A real-world study, 2024, pp.30, 345~359

관련 논문AI추천